Why the study?
Diagnosing NASH requires liver biopsy, which is invasive, prone to variability, and impractical for up to 1 billion affected individuals, highlighting an unmet need for non-invasive imaging biomarkers.
Can non-invasive imaging biomarkers accurately diagnose and stage NAFLD, NASH, and liver fibrosis compared to liver biopsy?
Can non-invasive imaging biomarkers accurately diagnose and stage NAFLD, NASH, and liver fibrosis compared to liver biopsy?
Non-invasive imaging modalities like MRI-PDFF and elastography offer reliable alternatives to liver biopsy for diagnosing and monitoring NAFLD and liver fibrosis.
No takes yet. Share an insight, caveat, or question.
Supports non-invasive monitoring in NAFLD; leaves open prospective validation for NASH diagnosis.
Ajmera et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: